Erschienen in:
01.03.2007 | Clinical-Patient Studies
Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma
verfasst von:
Marc C. Chamberlain, Michael J. Glantz, Lisa Chalmers, Alixis Van Horn, Andrew E. Sloan
Erschienen in:
Journal of Neuro-Oncology
|
Ausgabe 1/2007
Einloggen, um Zugang zu erhalten
Abstract
Concurrent temozolomide (TMZ) and radiotherapy is the new standard of care for patients with newly diagnosed glioblastoma. In 51 consecutive patients treated according to this regimen, 7 patients (14%) manifested surgically confirmed early necrosis without evidence of recurrent tumor. This observation suggests that daily TMZ may represent a potent radiosensitizing regimen.